Hwang, You-Cheol; Yoon, Kun-Ho; Cha, Bong-Soo; Lee, Kwan-Woo; Jang, Hak Chul; Min, Kyung Wan; Chung, Choon Hee; Lee, Moon-Kyu
International journal of clinical practice
2017Aug ; 5 ( 34 ) :.
PMID : 28840637
ÀúÀÚ »ó¼¼Á¤º¸
Hwang, You-Cheol -
Yoon, Kun-Ho -
Cha, Bong-Soo -
Lee, Kwan-Woo -
Jang, Hak Chul -
Min, Kyung Wan -
Chung, Choon Hee -
Lee, Moon-Kyu -
ABSTRACT
BACKGROUND: It has been suggested that renoprotection with calcium channel blockers (CCBs) may differ. This study aimed to compare the anti-proteinuric effect of different CCBs in patients with type 2 diabetes (T2D).
METHODS: A multicentre, randomized, open-label, active-controlled study was performed in seven centres in Korea. A total of 74 patients with T2D and microalbuminuria treated with renin-angiotensin system (RAS) blockers were randomized to a cilnidipine 10?mg treatment (n=38) or amlodipine 5?mg treatment (n=36).
RESULTS: Urine albumin to creatinine ratio (ACR) reduction was similar between the two groups at 12?weeks (-53.0±123.2?mg/g in cilnidipine group and -35.7±83.6?mg/g in amlodipine group, P=.29) or 24?weeks (-57.3±106.9?mg/g in cilnidipine group and -20.0±110.4?mg/g in amlodipine group, P=.24). In a subgroup analysis, cilnidipine treatment showed a larger ACR reduction than amlodipine treatment at 12?weeks (-84.7±106.8?mg/g in cilnidipine group and -9.5±79.2?mg/g in amlodipine group, P=.01) and 24?weeks (-84.0±111.7?mg/g in cilnidipine group and 14.6±119.4?mg/g in amlodipine group, P=.008), particularly in patients with a longer duration of diabetes more than 10?years.
CONCLUSIONS: Cilnidipine did not show any additional anti-albuminuric effect compared with amlodipine in patients with T2D and microalbuminuria treated with an RAS blocker. However, the anti-albuminuric effect of cilnidipine might differ according to the duration of diabetes. CI - ??2017 The Authors. International Journal of Clinical Practice Published by John Wiley & Sons Ltd.
na
¸µÅ©